NASDAQ$INVA
Innoviva Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported third quarter 2022 financial results and highlighted recent company progress.
Innoviva reported strong revenue from its diversified core royalty business despite challenging market conditions. The acquisitions of Entasis and La Jolla have given the company a strong footprint in the hospital and infectious disease space.
- RELVAR®/BREO® ELLIPTA® global net sales grew slightly compared to third quarter 2021, with U.S. net sales growth compensating for foreign currency changes and a slowdown in non-U.S. markets.
- ANORO® ELLIPTA® global net sales decreased by 15% compared to third quarter of 2021 mainly due to pricing pressures and foreign currency changes.
- Innoviva advanced its strategy with the acquisitions of Entasis and La Jolla, giving it a strong footprint in the hospital and infectious disease space.
- The company remains committed to a disciplined, thoughtful, and thorough approach to capital allocation.
Headline financials
Revenue & EPS history
Innoviva · Revenue · Quarterly
$67.3M
Forward guidance
No forward guidance was provided in the press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.4%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+2.8%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+19.4%
Q1 2012
Best reaction
-15.1%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -0.6% | -0.6% | |
| Q4 2025 | -2.7% | -8.0% | -6.5% | |
| Q3 2025 | +13.1% | +20.1% | +13.8% | |
| Q1 2025 | -0.9% | -2.6% | +15.2% | |
| Q4 2024 | -2.0% | -1.8% | +1.6% | |
| Q3 2024 | +2.9% | +3.6% | -2.0% | |
| Q2 2024 | +1.6% | -3.6% | +2.1% | |
| Q1 2024 | -1.5% | +4.2% | +3.9% | |
| Q4 2023 | -0.7% | -3.1% | -0.7% | |
| Q3 2023 | +7.0% | +10.0% | +12.7% | |
| Q2 2023 | -1.3% | +1.3% | -4.0% | |
| Q1 2023 | +4.5% | +8.5% | +17.5% | |
| Q4 2022 | -5.2% | -8.3% | -7.0% | |
| Q3 2022 | +5.1% | +2.6% | +2.5% | |
| Q2 2022 | -1.7% | -1.3% | -8.0% | |
| Q1 2022 | +0.9% | -5.2% | -10.2% | |
| Q4 2021 | +13.7% | +24.5% | +19.2% | |
| Q3 2021 | +8.8% | +9.2% | +6.3% | |
| Q2 2021 | +6.3% | +10.2% | +10.7% | |
| Q1 2021 | +0.9% | +0.7% | +16.2% | |
| Q4 2020 | +1.0% | +1.3% | -7.3% | |
| Q3 2020 | +11.3% | +6.4% | +12.7% | |
| Q2 2020 | +0.4% | +0.7% | -15.0% | |
| Q1 2020 | +5.3% | -0.2% | +3.7% | |
| Q4 2019 | +3.5% | +3.5% | -6.1% | |
| Q3 2019 | +6.2% | +10.8% | +23.2% | |
| Q2 2019 | -15.1% | -10.4% | -16.1% | |
| Q1 2019 | +6.5% | +6.6% | -2.6% | |
| Q4 2018 | -3.3% | -6.1% | -14.2% | |
| Q3 2018 | +2.3% | +7.7% | +22.6% | |
| Q2 2018 | -1.2% | +1.5% | +1.3% | |
| Q1 2018 | -2.9% | -0.3% | -1.5% | |
| Q4 2017 | +8.5% | +19.5% | +14.2% | |
| Q3 2017 | -11.9% | -14.0% | -4.5% | |
| Q2 2017 | +4.3% | +4.7% | -2.1% | |
| Q1 2017 | -8.3% | -9.6% | -5.3% | |
| Q4 2016 | +1.7% | +7.9% | +15.8% | |
| Q3 2016 | -1.6% | +4.2% | +12.9% | |
| Q2 2016 | +9.2% | +8.9% | -3.5% | |
| Q1 2016 | -1.0% | — | — | |
| Q4 2015 | +14.6% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | -10.8% | — | — | |
| Q1 2015 | -6.3% | — | — | |
| Q4 2014 | +10.8% | — | — | |
| Q3 2014 | -5.0% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -1.1% | — | — | |
| Q4 2013 | -2.1% | — | — | |
| Q3 2013 | +8.3% | — | — | |
| Q2 2013 | -3.7% | — | — | |
| Q1 2013 | +11.3% | — | — | |
| Q4 2012 | -4.9% | — | — | |
| Q3 2012 | -9.4% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2011 | -1.9% | — | — | |
| Q1 2012 | +19.4% | — | — | |
| Q4 2011 | +0.8% | — | — | |
| Q3 2011 | +8.6% | — | — | |
| Q2 2011 | +1.3% | — | — | |
| Q4 2010 | -1.1% | — | — | |
| Q3 2010 | +2.7% | — | — | |
| Q2 2010 | +8.0% | — | — | |
| Q1 2010 | -9.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro